On May 21, 2026 Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, reported that data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests will be presented at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting in Chicago, taking place May 29 – June 2. The OPTIMA and ENZAMET trial presentations are expected to provide practice-changing evidence demonstrating how Veracyte’s genomic tests can guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The OPTIMA study is a prospective, randomized trial led by University College London (UCL) and supported by the National Institute for Health Research (NIHR). The study enrolled more than 4,400 patients and was designed to address a key clinical question: which patients would benefit from chemotherapy, and which may be able to safely avoid it, and its long-term toxicities. The study results demonstrating how the Prosigna test can guide adjuvant chemotherapy decisions in patients with high-risk breast cancer will be presented by Dr. Rob Stein of UCL and OPTIMA Trial Chief Investigator, on Saturday, May 30 during the breast cancer session.

"The OPTIMA trial results represent a major milestone in precision breast oncology and will provide Level 1A evidence supporting Prosigna-guided treatment decisions," said Kelly Marcom, M.D., Veracyte’s medical director, Breast Cancer. "These findings have the potential to transform how clinicians treat a large population of patients with breast cancer, helping them to personalize their patient’s treatment choices using the genomic insights that the Prosigna test provides."

The ENZAMET trial is an international, prospective, randomized study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Dr. Christopher Sweeney of South Australian Immunogenomics Cancer Institute, Adelaide University, will present data on Saturday, May 30 during the Genitourinary Cancer session on Decipher Prostate’s ability to predict treatment benefit with the chemotherapy docetaxel in metastatic, hormone-sensitive prostate cancer. The independent analysis evaluated how the Decipher test can help identify which patients are most likely to benefit from treatment intensification with triplet therapy (docetaxel to standard of cancer hormonal therapy).

"Together, these studies provide practice-changing evidence supporting the use of Veracyte’s tests in guiding treatment decisions across cancer types," said Phillip Febbo, M.D., Veracyte’s chief scientific and medical officer. "In practice, this means clinicians can more confidently match treatment intensity to individual patient risk, helping ensure the right level of care while avoiding unnecessary treatment and its side effects, for both breast and prostate cancer patients."

Additional research to be presented at ASCO (Free ASCO Whitepaper) supports the company’s mission to transform cancer care for patients all over the world.

Oral Presentations at ASCO (Free ASCO Whitepaper) 2026 Annual Meeting

Title: First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer
Presenter: Robert Stein, PhD, MBBChir, FRC, National Institute for Health Research University College London Hospitals Biomedical Research Centre
Session Title: Breast Cancer—Local/Regional/Adjuvant
Date/Time: Saturday, May 30, 2026, 1:15 PM CT
Location: Hall B1
Title: Clinico-Transcriptomic Risk Stratification to Guide Abiraterone Treatment Intensification in High-Risk Prostate Cancer: A Combined Analysis of NRG/RTOG 9202, 9413, 9902, and 0521
Presenter: Krishnan R Patel, MD, MHS, Radiation Oncology Branch, National Cancer Institute, NIH
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Date/Time: Saturday, May 30, 2026, 3:00 PM CT
Location: Hall D1
Title: Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study
Presenter: Christopher Sweeney, MBBS, South Australian Immunogenomics Cancer Institute, Adelaide University
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Date/Time: Saturday, May 30, 2026, 3:12 PM CT
Location: Hall D1
Title: Genomic classifier–driven NCCN risk reclassification to track distinct transcriptomic signatures in early prostate cancer
Presenter: Daniel Keizman, MD, Tel Aviv Sourasky Medical Center, Israel
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Date/Time: Sunday, May 31, 2026, 4:36 PM CT
Location: Hall D1
Additional Posters at ASCO (Free ASCO Whitepaper)

Abstract #1660 | Poster bd #578: Titled: Practice patterns and outcomes by genomic risk in octogenarians with high-risk localized prostate cancer: a national real-world data analysis. Presenter: James Janopaul-Naylor – Saturday May 30, 2026 at 9:00 AM CDT, Hall A
Abstract #4619 | Poster bd #98: Titled: Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial. Presenter: Brigida A. Maiorano – Sunday, May 31, 2026 at 9:00 AM CDT, Hall A
Abstract #5114 | Poster bd #209: Titled: Assessing the Clinical and Biological Associations Between Artera Multimodal Artificial Intelligence (MMAI) and Decipher Genomic Classifier (GC) in Localized Prostate Cancer (PCa). Presenter: Boon Hao Hong – Sunday, May 31, 2026 at 9:00 AM CDT, Hall A
Abstract #4617 | Poster bd #96: Titled: Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC). Presenter: Andrea Necchi – Sunday, May 31, 2026 at 9:00 AM CDT, Hall A
For more information, stop by Veracyte’s booth #13069 at the ASCO (Free ASCO Whitepaper) Annual Meeting or visit the company’s website here.

(Press release, Veracyte, MAY 21, 2026, View Source [SID1234665938])

On May 21, 2026 Kelun reported two registrational studies of the trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT)(佳泰莱) and the next‑generation selective rearranged during transfection (RET) inhibitor lunbotinib fumarate (A400/EP0031,宁泰莱) from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) have been selected for oral presentation session on Lung Cancer – Non-Small Cell Metastatic. The full text of the related abstracts were published on the ASCO (Free ASCO Whitepaper) official website[2] on May 21, 2026, local time. Key highlights are summarized as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Study 1

Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, controlled Phase III OptiTROP-Lung05 study, to be presented as an oral presentation scheduled on May 29, 2026, 3:12 PM-3:24 PM CDT (Abstract #8506: Lung Cancer – Non-Small Cell Metastatic)

A total of 413 patients with previously untreated locally advanced or metastatic NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations and with programmed death ligand 1 (PD-L1) positive (defined as tumor proportion score (TPS) ≥1%), covering both squamous and non‑squamous histologies, were enrolled and randomized (1:1) to receive sac-TMT (4mg/kg Q2W) plus pembrolizumab (400mg Q6W) or pembrolizumab monotherapy (400mg Q6W). The primary endpoint was progression‑free survival (PFS) assessed by blinded independent central review (BICR), and the key secondary endpoint was overall survival (OS). As of September 29, 2025, the median follow-up was 10.5 months.

The results demonstrated that：

Significant PFS improvement: PFS assessed by BICR was significantly improved in the sac-TMT plus pembrolizumab group compared with the pembrolizumab group, with a median PFS of not reached (NR) versus 5.7 months (hazard ratio (HR)=0.35; 95% confidence interval (CI): 0.26–0.47; p<0.0001).
Substantially higher response rate: The objective response rate (ORR) assessed by BICR was 70.2% in the sac-TMT plus pembrolizumab group versus 42.0% in the pembrolizumab group.
Positive OS trend though immature (HR=0.55; 95% CI: 0.36–0.85).
Consistent benefit across prespecified subgroups: the HR for PFS in patients with PD-L1 TPS 1-49% and TPS ≥ 50% were 0.28 (95% CI, 0.19-0.41) and 0.47 (95% CI, 0.29-0.77), respectively; the HR for PFS in patients with non-squamous and squamous NSCLC were 0.28 (95% CI, 0.18-0.43) and 0.44 (95% CI, 0.29-0.66).
In terms of safety, grade≥ 3 treatment-emergent adverse events (TEAEs) occurred in 55.3% of patients in the sac-TMT plus pembrolizumab group versus 31.4% in the pembrolizumab group. TEAEs leading to permanent discontinuation of sac-TMT and pembrolizumab occurred in 3.8% and 5.3% of patients, respectively, while TEAEs leading to permanent discontinuation occurred in 4.9% of patients in the pembrolizumab group.

OptiTROP-Lung05 is the first Phase III clinical study demonstrating a significant improvement in PFS and a positive trend in OS with an ADC combined with pembrolizumab compared to pembrolizumab in first-line treatment for PD-L1 positive advanced NSCLC. Based on these results, a supplemental New Drug Application (sNDA) for this combination regimen has been accepted for review and included in the priority review and approval process by the National Medical Products Administration (NMPA) in China.

Study 2

Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), to be presented as an oral presentation scheduled on May 29, 2026, 2:36 PM-2:48 PM CDT (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic)

As of October 29, 2025, 71 patients with prior platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients) were enrolled, with median follow-up of 22.6 and 20.7 months.

The study demonstrated that：

Independent Review Committee (IRC)-assessed confirmed ORR was 87.1% (95% CI: 77.0-93.9) in pre-treated patients and 81.3% (95% CI: 71.8-88.7) in treatment-naïve patients;
Median PFS was 27.5 months in pre-treated patients (immature) and NR in treatment-naïve patients, with 24-month PFS rates of 52.1% and 59.9%, respectively;
Median OS was not reached in either group, with 24-month OS rates of 65.7% in pre-treated patients and 74.1% in treatment-naïve patients.
Among patients with baseline brain metastases (23 pre-treated, 16 treatment-naïve), ORR was 82.6% and 75.0%, respectively, and 6 patients in each cohort had complete intracranial response.
The safety profile was manageable, with no new signals identified. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 40.5% of patients. Only two patients (1.2%) permanently discontinued treatment due to TRAEs. No fatal TRAEs occurred.

Based on the results of this study, the new drug application (NDA) for lunbotinib fumarate for the treatment of adult patients with RET fusion-positive locally advanced or metastatic NSCLC has been accepted for review by the NMPA.

About sac-TMT(佳泰莱)

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR–tyrosine kinase inhibitor (EGFR-TKI) therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA[3]) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and ALK-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

[1] Trade name to be approved by NMPA.

[2] View Source

[3] KEYTRUDA (pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About Lunbotinib Fumarate (A400/EP0031,宁泰莱)

Lunbotinib fumarate is a novel, next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of lunbotinib fumarate has been accepted for review by the NMPA of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.

In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, lunbotinib fumarate was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive advanced NSCLC.

(Press release, Kelun, MAY 21, 2026, View Source [SID1234665954])

On May 21, 2026 Flatiron Health reported its presence at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting happening from May 29 – June 2, 2026, in Chicago, Illinois. Flatiron’s high-quality real-world data and innovative research capabilities are featured across 25+ research acceptances, including 14 Flatiron-authored poster presentations and online publications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Flatiron’s presence at ASCO (Free ASCO Whitepaper) 2026 closely follows the launch of Flatiron Telescope, a multi-agent adaptive analytics platform designed to help life sciences teams find the right patients faster, assess study feasibility in real time, and generate oncology insights on demand. Flatiron Telescope will be demonstrated at the company’s booth (#21149) for attendees to build and iterate on patient cohorts using natural language and generate insights in real time.

"Our presence at ASCO (Free ASCO Whitepaper) 2026 proves that innovation and rigor aren’t at odds—they reinforce each other," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. "From digital twins that simulate patient outcomes to LLM-enabled treatment pattern analysis, our work demonstrates that Flatiron is defining—not just participating in—the evolution of oncology evidence. These 25+ acceptances showcase our unified, global oncology engine and reinforce our position as the gold standard in oncology intelligence, trusted to guide the highest-stakes decisions across the industry."

Research highlights include:

Digital twin modeling for treatment prediction: validating novel counterfactual prediction approaches in NSCLC using clinical trial data, demonstrating how AI-enabled simulation can move beyond observational analysis to model patient outcomes under different treatment scenarios
Physician adoption of landmark clinical trial findings: a large-language model-based analysis documenting how ASCO (Free ASCO Whitepaper) plenaries translate to clinical decision-making in real-world practice, the largest such analysis of clinician-patient trial discussions to date
Recurrence risk prediction in early breast cancer: leveraging multi-site observational data to build predictive models for early breast cancer populations, showing how scale enables discovery in underrepresented patient groups
Post-operative circulating tumor DNA as a prognostic indicator: examining ctDNA’s role in identifying high-recurrence risk in muscle-invasive and locally advanced bladder cancer, demonstrating the value of real-world biomarker data in routine practice
Real-world treatment patterns in platinum-resistant ovarian cancer: analyzing platinum re-challenge outcomes in a population with limited evidence guidance, highlighting how Flatiron’s depth of longitudinal data reveals clinical practices that diverge from trial design and guidelines
Join Flatiron Health at booth #21149 for a demo of Flatiron Telescope and follow Flatiron Health on X and LinkedIn for more updates from #ASCO26.

Poster Presentations
From plenary to practice: a large language model (LLM)-based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoption
Aaron B Cohen, Tori Williams, Charu Aggarwal, Angela M DeMichele, Ritvik Vasudevan, Niquelle Brown Wadé, Shreya Balakrishna Rosseau, Erin Fidyk, Blythe Adamson
Author affiliations: Penn Medicine, Flatiron Health
Abstract Number: 1583
Poster Session: Care Delivery/Models of Care
Poster Board: 501
Date and Time: May 30, 2026, 9-12 PM

External validation of a deep learning CT biomarker to predict first-line immune checkpoint inhibitor monotherapy-associated survival in PD-L1-high metastatic non-small cell lung cancer
Ravi B. Parikh, Jacqueline Law, Lauren M. Damato, Paul M. Novotny, Joel Brooks, Ryan Beasley, Chiharu Sako, Petr Jordan, George R. Simon
Author affiliations: Emory University, Onc.AI, OhioHealth, Flatiron Health
Abstract Number: 2534
Poster Session: Developmental Therapeutics—Immunotherapy
Poster Board: 324
Date and Time: May 30, 2026, 1:30- 4:30 PM

Prognostic value of post-operative circulating tumor DNA (ctDNA) in real-world treatment and outcomes among patients (pts) with muscle invasive (MIBC) and locally advanced (LA) bladder cancer (BC)
Khilna Patel, Danni Zhao, Erin Fidyk, Eunice A. Hankinson, Aashay Mahesh Mehta, Matthew Pesavento, Arun Sujenthiran
Abstract Number: 4600
Poster Session: Genitourinary Cancer—Kidney and Bladder
Poster Board: 79
Date and Time: May 31, 2026, 9-12 PM

Real-world second-line treatment patterns and outcomes by platinum sensitivity in extensive-stage small cell lung cancer in the post-immunotherapy era
Catherine Rinaldi, Samantha Reiss, Jenna Collins, Karen Schwed, Michael Chiu, Emily Castellanos
Abstract Number: 8083
Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Board: 557
Date and Time: May 31, 2026, 9-12 PM

Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first-line induction and maintenance regimens in extensive-stage small cell lung cancer
Apar Kishor Ganti, Jeremy Snider, Jessie T. Yan, Catherine Rinaldi, Amy Nguyen, Badri Rengarajan, Deb Profant, Douglas S. Fuller, Ellen Hu, Trong Kim Le, Navit Naveh, Xiaozhou Fan
Author affiliations: Jazz Pharmaceuticals, Nebraska Western Iowa Health Care System/University of Nebraska Medical Center, Flatiron Health
Abstract Number: 8093
Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Board: 567
Date and Time: May 31, 2026, 9-12 PM

A risk stratification schema for patients with non-small cell lung cancer with multiple organ metastases
Gabriela Esnaola, Mengru Wang, Benjamin Resio, Alexander Pan, Daniel Lee, Aaron B. Cohen, Maneet Kaur, Madeleine Schmitter, Jeffrey J. Ishizuka, Kelly Olino
Author affiliations: Yale School of Medicine, Dana-Farber Cancer Institute, Flatiron Health
Abstract Number: 11138
Poster Session: Quality Care/Health Services Research Track
Poster Board: 121
Date and time: June 1, 2026, 9-12pm

Platinum re-challenge in platinum-resistant ovarian cancer: real-world patterns and outcomes
Prakirthi Yerram, Matt Bye, Khilna Patel, Nicole Nasrallah, Michael Curry, Emily Castellanos
Abstract Number: 5566
Poster Session: Gynecologic Cancer
Poster Board: 232
Date and Time: June 1, 2026, 9-12pm

Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)
Michael Peng, Gabriel Rios, Melissa Estevez, Jamie Colasurdo, Mohammad Forouzanfar, Kelly Hoang, Meng Wang
Author affiliations: Gilead Sciences, IQVIA, Flatiron Health
Abstract Number: 1025
Poster Session: Breast Cancer—Metastatic
Poster Board: 139
Date and Time: June 1, 2026, 1:30-4:30 PM

RW post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with HR+/HER2− metastatic breast cancer (MBC) in US.
Vk Gadi, Lowell L. Hart, Paolo Tarantino, Priyanka Sharma, Sarah L. Sammons, Panagiotis Mayros, Maneet Kaur, Nada Boualam, Catherine Keane, Gary M. Sopher, Purnima Pathak, Hope S. Rugo
Author affiliations: University of Illinois Cancer Center, Wake Forest University/Florida Cancer Specialists, Harvard Medical School, University of Kansas Medical Center, Dana-Farber Cancer Institute, Novartis, City of Hope Comprehensive Cancer Center, Flatiron Health
Abstract Number: 1073
Poster Session: Breast Cancer—Metastatic
Poster Board: 187
Date and Time: June 1, 2026, 1:30-4:30 PM

Recurrence risk prediction using a large, multi-site observational dataset of patients with early breast cancer including early-onset disease
Lilia Bouzit, Gabriel Rios, Smriti Karwa, Erin Fidyk, Catherine Keane, Melissa Estevez
Abstract Number: 547
Poster Session: Cancer—Local/Regional/Adjuvant
Poster Board: 32
Date and Time: June 1, 2026, 1:30-4:30 PM

Online Acceptances
Digital twin models for counterfactual prediction in NSCLC: a validation study using clinical trial data
Aaron B Cohen, Sandra Giffith, Melissa Estevez, Brandon Arnieri, Matt H Secrest, Joe Manfredonia, Marcello Ricottone, Richard Knoche, Jacqueline Law, Melina Marmarelis
Author affiliations: Genentech, University of Pennsylvania, Flatiron Health
Abstract Number for Publication: e20517

Real-world treatment patterns and outcomes among patients with high-risk and very high-risk non-metastatic prostate cancer
Eunice A. Hankinson,Yunzhi Qian, Patrick Ward, Khilna Patel, Aaron Dolor, Arun Sujenthiran
Abstract Number for Publication: e17120

Drivers of organotropism and patterns of metastatic progression in metastatic non-small cell lung cancer
Gabriela Esnaola, Benjamin Resio, Alexander Pan, Daniel Lee, Aaron B. Cohen, Mengru Wang, Madeleine Schmitter, Jeffrey J. Ishizuka, Kelly Olin
Author affiliations: Yale School of Medicine, Dana-Farber Cancer Institute, Flatiron Health
Abstract Number for Publication: e20541

Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United States
Lauren Damato, Noelle S. Liao, Jonathan Bryan, Eunice A. Hankinson, Emily Castellanos
Abstract Number for Publication: e16039

(Press release, Flatiron Health, MAY 21, 2026, View Source [SID1234665970])

On May 21, 2026 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, reported that it will host an investor webcast featuring members of management on June 3, 2026 at 8:30 am ET to review updated data from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care regimens (FOLFIRI/bevacizumab or FOLFOX/bevacizumab) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The updated CRDF-004 data will first be presented during a rapid oral session at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting on June 2, 2026 at 8:00 am CT/9:00 am ET and will build on the CRDF-004 data previously presented in January 2026. More details about the oral presentation are available on the Company’s website here and the full abstract is now available on the ASCO (Free ASCO Whitepaper) website.

Investor Webcast Details
The investor webcast will take place on June 3 at 8:30 am ET. To register for and access the live webcast, please visit the "Events" page of the Cardiff Oncology website.

About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor advancing toward a registrational trial in first-line RAS-mutated metastatic colorectal cancer (mCRC). In a randomized Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab (first-line standard-of-care) demonstrated dose-dependent improvements in overall response rate and progression-free survival compared to standard-of-care alone, building on findings from a prior Phase 2 trial in second-line RAS-mutated mCRC. Based on these results, the Company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational trial in first-line patients with RAS-mutated mCRC.

Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).

(Press release, Cardiff Oncology, MAY 21, 2026, View Source [SID1234665986])

On May 21, 2026 Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, reported that the Company’s management team will host a conference call and webcast on Tuesday, May 26 at 8:00 a.m. EDT to discuss updated data for its Phase 1/2 study of CRB-701, a next-generation Nectin-4 antibody drug candidate (ADC), in both head and neck squamous cell carcinoma (HNSCC) as well as cervical cancer. The data, which will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, represent an April 1, 2026 data cut, and will include clinical response durability data as well as HNSCC patient subgroup analysis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Corbus also announced today the appointment of former Evercore Managing Director Nishant Saxena as the Company’s first Chief Business Officer, as it advances toward two key anticipated pipeline milestones this summer: the initiation of a registrational study of CRB-701 in second-line HNSCC and the completion of the CANYON-1 Phase 1b dose-ranging, 16-week study (n=240) for CRB-913, a highly peripherally restricted oral CB1 inverse agonist.

"Nishant is an accomplished industry executive with deep expertise across mergers and acquisitions, licensing, partnerships, and capital markets," said Yuval Cohen, Ph.D., CEO of Corbus. "His proven track record of unlocking and delivering value coincides with our transition from an early clinical-stage company to one entering registrational-stage clinical development. We are excited and grateful that he has chosen to join the Corbus team."

Mr. Saxena commented, "The emerging clinical data for CRB-701 in oncology and CRB-913 in obesity are very encouraging, and the Corbus team has done an incredible job advancing these two assets toward important milestones this year," said Mr. Saxena. "I am excited by the clinical and commercial potential for both of these assets, and I look forward to working with Yuval and the rest of the leadership team to advance this portfolio toward its full value and impact."

Nishant Saxena Biographical Details

Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was Chief Financial Officer at Jeune Aesthetics, Inc., a wholly owned subsidiary of Krystal Biotech, Inc. (NASDAQ: KRYS). Previously, Mr. Saxena spent over 15 years at Evercore, most recently as a Managing Director in the healthcare group, where he advised on transactions totaling over $500 billion in aggregate value. Mr. Saxena led numerous client engagements and advised on mergers and acquisitions, private placements, initial public offerings, follow-on offerings, partnerships, and structured financing. Earlier in his career, Mr. Saxena held positions of increasing responsibility in private equity, venture capital, and investment advisory firms. Mr. Saxena received a B.S. in Economics and an MBA from the Wharton School at the University of Pennsylvania.

Pre-2026 ASCO (Free ASCO Whitepaper) Conference Call & Webcast Registration Details

Date: Tuesday, May 26, 2026
Time: 8:00 a.m. EDT
Investors Dial 1-877-704-4453
Int’l Investors Dial 1-201-389-0920
Conference ID 13760531
Webcast: Click here
CallMe: Click here

A replay will be available on the Corbus website.

CRB-701 2026 ASCO (Free ASCO Whitepaper) Data Presentation Details

The oral presentation titled, "A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer," will be presented by Professor Yohann Loriot, Gustave Roussy (Paris) on Friday, May 29 at 4:57 p.m. CDT (Abstract #5508).

The poster presentation titled, "A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma," will be presented by Charlene Mantia, M.D., Dana-Farber Cancer Institute (Boston) on Saturday, May 30 at 4:30 p.m. CDT (Abstract #6062/Poster #519).

2026 ASCO (Free ASCO Whitepaper) HNSCC KOL Event Details

Corbus will host an in-person and virtual KOL event during the 2026 ASCO (Free ASCO Whitepaper) to discuss the updated data from the Phase 1/2 clinical study of CRB-701 in 75 participants with HNSCC.

Date: Monday, June 1, 2026
Time: 6:30 a.m. CDT
Location: Marriott Marquis Chicago
Participants: Corbus Management Team, joined by leading HNSCC Experts:
Ari Rosenberg, M.D., University of Chicago
Glenn Hanna, M.D., Dana-Farber Cancer Institute
Cesar Augusto Perez Batista, M.D., Sarah Cannon Research Institute

A live question-and-answer session will follow the formal presentation. To register for the KOL event, click here. A replay of the event will also be available on the Corbus website.

(Press release, Corbus Pharmaceuticals, MAY 21, 2026, View Source [SID1234665923])